Grant: Discovery Grants Program - Individual
University of Saskatchewan
$40,000.00
Inducing respiratory mucosal immunity in cattle by design of next-generation thermostable ribonucleic acid vaccines
EF 2024-25
Résumé
Infectious diseases of cattle remain a considerable challenge that impact animal health and food security. Veterinary vaccines with the capacity for rapid development during disease outbreaks and potential for low-cost manufacture and distribution are highly desired. Messenger RNA (mRNA) formulated with lipid nanoparticles (LNPs) offer new, exciting platform for such vaccines. However, the major bottlenecks to the application of mRNA vaccines in farm animals is their limited storage/shelf stability and the requirements for multiple boosters and ultra-cold storage temperatures, which increases the overall cost of the final vaccine product. The target product profile for veterinary vaccines is a single shot, needle free, low cost, and multivalent vaccine inducing long lasting immunity. The next generation of RNA cargo is self-amplifying RNA (saRNA), based of alphaviral RNA backbones that allow self-replication within cells and enables protein expression at 10-fold less mRNA doses. Thus, the potential advantage of saRNA vaccines is in dose sparing and therefore lower vaccine costs as compared to the mRNA vaccines. The current mRNA-LNP vaccines have poor colloidal stability and can only be stored for a short term at 2 to 8 °C, but for long-term storage, -80 to -20 °C temperatures are required. Moreover, the first-generation mRNA vaccines do no induce mucosal immunity characterized by protective T cells in the nasal passages and lungs. To this end, we have invented a unique RNA delivery technology based on lipid-polymer hybrid nanoparticles (hLPNs) that have improved colloidal stability than LNPs and enable post-manufacture processing of liquid hLPN formulations into dry powder formulations. However, the ability of RNA loaded hLPNs to induce activation of antigen presenting cells and induce immunogenicity in cattle is unkown. In this research project, we will generate this information. I hypothesize that by an improved formulation design and administration, we can develop stable saRNA vaccine formulations that can navigate through the pulmonary biological barriers and induce protective mucosal immunity. I will test my hypothesis through an interdisciplinary approach by applying tools in molecular biology, drug delivery, and immunology. The objectives of the proposal are to (i) formulate and characterize vaccines based on hLPNs encapsulating saRNA encoding for antigenic protein, (ii) prepare and characterize the dry powder versions of the saRNA vaccines for nasal administration, and (iii) evaluate the immunogenicity and efficacy of the thermostable saRNA vaccines in disease challenge models. The results from the project can be used to optimize thermostable saRNA vaccines for inducing robust protective mucosal immunity in cattle. The optimized saRNA vaccines can readily be adapted to counter emerging and reemerging pathogens and hence be important for the future preparedness for animal disease outbreaks in cattle and other farm animals.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Saskatchewan, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2024-03947
Name nom
Thakur, Aneesh
Department département
VIDO
Organization id
16
Institution établissement
University of Saskatchewan
Province en
Saskatchewan
Province fr
Saskatchewan
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
40000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1502
Committee name en
Biological Systems and Functions
Committee name fr
Systèmes et fonctions biologiques
Area of application code
101
Area of application group en
Agriculture and primary food production
Area of application group fr
Agriculture et produits alimentaires primaires
Area of application en
Animal production and animal primary products
Area of application fr
Production animale et produits animaux primaires
Research subject code
5512
Research subject group en
Animal biology
Research subject group fr
Biologie animale
Research subject en
Veterinary sciences
Research subject fr
Médecine vétérinaire
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Inducing respiratory mucosal immunity in cattle by design of next-generation thermostable ribonucleic acid vaccines
Keywords
cattle; rna; nanoparticles; formulation; drug delivery; immunology; mucosal immunity; vaccines; particle engineering; thermostability
Application summary
Infectious diseases of cattle remain a considerable challenge that impact animal health and food security. Veterinary vaccines with the capacity for rapid development during disease outbreaks and potential for low-cost manufacture and distribution are highly desired. Messenger RNA (mRNA) formulated with lipid nanoparticles (LNPs) offer new, exciting platform for such vaccines. However, the major bottlenecks to the application of mRNA vaccines in farm animals is their limited storage/shelf stability and the requirements for multiple boosters and ultra-cold storage temperatures, which increases the overall cost of the final vaccine product. The target product profile for veterinary vaccines is a single shot, needle free, low cost, and multivalent vaccine inducing long lasting immunity. The next generation of RNA cargo is self-amplifying RNA (saRNA), based of alphaviral RNA backbones that allow self-replication within cells and enables protein expression at 10-fold less mRNA doses. Thus, the potential advantage of saRNA vaccines is in dose sparing and therefore lower vaccine costs as compared to the mRNA vaccines. The current mRNA-LNP vaccines have poor colloidal stability and can only be stored for a short term at 2 to 8 °C, but for long-term storage, -80 to -20 °C temperatures are required. Moreover, the first-generation mRNA vaccines do no induce mucosal immunity characterized by protective T cells in the nasal passages and lungs. To this end, we have invented a unique RNA delivery technology based on lipid-polymer hybrid nanoparticles (hLPNs) that have improved colloidal stability than LNPs and enable post-manufacture processing of liquid hLPN formulations into dry powder formulations. However, the ability of RNA loaded hLPNs to induce activation of antigen presenting cells and induce immunogenicity in cattle is unkown. In this research project, we will generate this information. I hypothesize that by an improved formulation design and administration, we can develop stable saRNA vaccine formulations that can navigate through the pulmonary biological barriers and induce protective mucosal immunity. I will test my hypothesis through an interdisciplinary approach by applying tools in molecular biology, drug delivery, and immunology. The objectives of the proposal are to (i) formulate and characterize vaccines based on hLPNs encapsulating saRNA encoding for antigenic protein, (ii) prepare and characterize the dry powder versions of the saRNA vaccines for nasal administration, and (iii) evaluate the immunogenicity and efficacy of the thermostable saRNA vaccines in disease challenge models. The results from the project can be used to optimize thermostable saRNA vaccines for inducing robust protective mucosal immunity in cattle. The optimized saRNA vaccines can readily be adapted to counter emerging and reemerging pathogens and hence be important for the future preparedness for animal disease outbreaks in cattle and other farm animals.